投资者来访接待活动记录表 文件编号：ZJ17（ZD)R04 证券代码：002880 证券简称：卫光生物 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|-------------------------|--------------------------------------------------| | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | √ 业绩说明会 | | 投资者关系活动类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员 姓名 | 参与公司 2018 | 半年报业绩网上说明会的投资者 | | 时间 | 2018 年 8 月 21 | 日 15:00-17:00 | | | | | | 地点 | | 全景网"全景•路演天下"投资者互动平 | | | 台（ http://rs. p5w.net | ） （本次业绩说明会采用网络远程方式举 | | | | | | | 行） | | | 上市公司接 ...

证券代码：002880 证券简称：卫光生物 编号：2022-001 深圳市卫光生物制品股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------------------|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系 活动类 | □媒体采访 | □业绩说明会 | | 别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | 其他（电话会议） ...

Financial Performance - The company's revenue for Q3 2022 was ¥179,587,222.01, a decrease of 36.08% compared to the same period last year[7] - The net profit attributable to shareholders for Q3 2022 was ¥25,883,259.59, down 61.77% year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥24,407,396.29, reflecting a 62.79% decrease compared to the previous year[7] - Total operating revenue for the third quarter was CNY 411,433,957.15, a decrease of 33.3% compared to CNY 616,756,759.63 in the same period last year[26] - Net profit for the third quarter was CNY 72,732,672.12, a decline of 47.0% compared to CNY 137,229,657.84 in the previous year[28] - Earnings per share for the third quarter were CNY 0.3209, down from CNY 0.6070 in the same quarter last year[28] Cash Flow and Liquidity - The operating cash flow for the year-to-date period was -¥51,123,244.76, a decline of 142.49% year-on-year[7] - Operating cash inflow for the current period was CNY 514,872,246.56, a decrease of 21.1% from CNY 652,908,945.47 in the previous period[32] - Net cash flow from operating activities was CNY -51,123,244.76, compared to CNY 120,331,844.55 in the previous period[32] - Cash and cash equivalents at the end of the period amounted to CNY 477,262,302.52, up from CNY 280,008,234.42 in the previous period[35] - The company’s cash flow from operating activities showed a significant decline, indicating potential challenges in revenue generation[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,458,912,882.11, an increase of 22.73% from the end of the previous year[7] - Total liabilities rose to CNY 639,765,748.40, compared to CNY 215,230,209.78 in the previous year[25] - The total equity attributable to shareholders of the parent company was CNY 1,796,135,412.71, up from CNY 1,768,725,498.43 in the previous year[25] Inventory and Borrowings - The company's inventory increased by 47.23% compared to the end of the previous year, attributed to higher raw material levels[11] - The company experienced a 300% increase in short-term borrowings compared to the end of the previous year, primarily due to operational needs[11] Government Support and Non-Operating Income - The company received government subsidies amounting to ¥1,939,197.97 during the reporting period, contributing to an increase in non-operating income[8] Research and Development - Research and development expenses for the third quarter were CNY 28,275,340.82, down from CNY 34,650,925.82 year-over-year[26] Future Plans and Strategies - The company is actively pursuing new product development and market expansion strategies, although specific details are not provided in the current report[18] - The company has disclosed its intention to issue new shares, which is currently under review by the China Securities Regulatory Commission[16] Employee Engagement - The company has implemented an employee stock ownership plan, which is set to expire soon, indicating a focus on employee engagement and retention[19]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥231,846,735.14, a decrease of 30.95% compared to ¥335,788,141.61 in the same period last year[24]. - The net profit attributable to shareholders was ¥46,886,654.69, down 32.98% from ¥69,960,029.07 year-on-year[24]. - The net profit after deducting non-recurring gains and losses was ¥42,913,847.59, a decline of 34.90% compared to ¥65,914,936.94 in the previous year[24]. - Basic earnings per share were ¥0.2067, down 33.00% from ¥0.3085 year-on-year[24]. - The operating cost decreased by 35.69% to ¥128,523,771.64 from ¥199,846,790.10, mainly due to the decline in operating revenue[52]. - The company reported a net profit of ¥46,832,505.44, a decline of 32.7% compared to ¥69,697,400.68 in the first half of 2021[182]. - The total comprehensive income for the first half of 2022 was CNY 52,840,879.73, compared to CNY 77,259,232.72 in the same period of 2021[189]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥14,381,375.99, a significant decrease of 132.42% from ¥44,354,483.29 in the same period last year[24]. - The net increase in cash and cash equivalents was ¥217,646,017.16, a significant increase of 238.34% compared to -¥157,325,959.57 in the previous year[52]. - Cash flow from operating activities showed a net outflow of CNY 14,381,375.99, contrasting with a net inflow of CNY 44,354,483.29 in the first half of 2021[190]. - The total cash and cash equivalents at the end of the first half of 2022 amounted to 418,717,741.28, up from 250,519,415.04 at the end of the first half of 2021[197]. Assets and Liabilities - Total assets increased by 19.52% to ¥2,394,529,773.93 from ¥2,003,504,959.66 at the end of the previous year[24]. - Total liabilities reached ¥601,282,806.90, significantly higher than ¥215,230,209.78, indicating a growth of around 179.5%[170]. - Short-term borrowings surged to ¥105,000,000.00 from ¥25,000,000.00, marking a 320% increase[170]. - The company's total liabilities amounted to CNY 332,267,601.89, compared to CNY 548,672,302.77 in the previous period[180]. Research and Development - Research and development investment decreased by 28.18% to ¥14,420,128.88 from ¥20,078,809.70[52]. - The company has a strong focus on R&D, with approximately 70 personnel dedicated to innovation, and has successfully submitted applications for new product approvals, including human coagulation factor VIII and a new intravenous immunoglobulin[44]. - The company is focused on improving its R&D management to mitigate risks associated with new product development, including potential delays and failures[82]. Market Position and Strategy - The company is positioned as one of the earliest in the industry to obtain GMP certification, enhancing its competitive edge[31]. - The introduction of centralized procurement for blood products is expected to accelerate industry differentiation and push companies towards innovation and product development[31]. - The company aims to become a pioneer in differentiated blood products in China and a new force in global biopharmaceuticals through strategic innovations[43]. - The company plans to focus on market expansion and new product development to improve future performance[180]. Operational Challenges - The company faces risks related to raw material supply shortages, particularly for blood plasma, due to stricter regulations and the impact of COVID-19[82]. - The company is facing uncertainties in plasma collection, production, and sales due to the recurring COVID-19 pandemic, despite taking proactive measures to mitigate its impact[84]. - The company experienced a slight increase in plasma collection volume during the reporting period, despite challenges from recurring COVID-19 outbreaks affecting collection stations[41]. Corporate Governance and Compliance - The company has not faced any regulatory measures or penalties from securities regulators in the past five years[139]. - The company has established a diverse communication channel for investors, including dedicated phone lines, emails, and performance briefings, to ensure transparency and protect the rights of shareholders and creditors[106]. - The company has received environmental impact assessment approvals for its production line expansion projects, ensuring adherence to environmental regulations[100].

深圳市卫光生物制品股份有限公司 2022 年第一季度报告 □ 是 √ 否 证券代码：002880 证券简称：卫光生物 公告编号：2022-028 深圳市卫光生物制品股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|-----------------------------| | | ...

深圳市卫光生物制品股份有限公司 2022 年第一季度报告 □ 是 √ 否 证券代码：002880 证券简称：卫光生物 公告编号：2022-028 深圳市卫光生物制品股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | | 本 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year growth of 15%[19] - The net profit attributable to shareholders was RMB 300 million, an increase of 20% compared to the previous year[19] - The company's operating revenue for 2021 was ¥907,434,715.73, representing a slight increase of 0.32% compared to ¥904,564,669.80 in 2020[6] - Net profit attributable to shareholders for 2021 was ¥205,436,658.57, an increase of 7.90% from ¥190,398,598.11 in 2020[6] - The net profit after deducting non-recurring gains and losses was ¥197,069,666.27, up by 6.88% from ¥184,382,231.71 in 2020[6] - The gross margin for the year was reported at 45%, reflecting improved operational efficiency[19] - Revenue from blood products accounted for 98.00% of total revenue, totaling CNY 889.29 million, which represents a decrease of 0.54% from CNY 894.11 million in 2020[57] - The company achieved a gross margin of 39.98% for blood products, an increase of 3.23% from the previous year[59] Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.00 per 10 shares, totaling approximately RMB 45.36 million[5] - The cash dividend represents 100% of the total distributable profit of 834,378,288.13 yuan for the reporting period[185] - The total cash dividend amount is fully funded from the company's after-tax profits[186] - The company did not propose a cash dividend distribution plan despite having a positive profit available for distribution to shareholders[177] Research and Development - The company has invested RMB 100 million in R&D for new product development, focusing on innovative biological products[19] - The company invested ¥47,795,916.52 in R&D, which is 5.27% of operating revenue, up from 4.99% the previous year[72] - The number of R&D personnel increased by 6.06% to 70, with a higher proportion of master's degree holders[72] - The company is focusing on the development of critical disease treatment drugs, including human coagulation factor VIII and new rabies vaccines[118] Market Expansion and Strategy - Future outlook includes an expansion plan targeting a 30% increase in market share within the next two years[19] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[19] - The company is actively expanding its marketing network, successfully entering dozens of top-tier hospitals in China and exporting some products to Venezuela and Brazil[50] - The company is committed to building a synthetic biology innovation ecosystem and aims to establish a specialized park for biopharmaceutical transformation in the Guangdong-Hong Kong-Macao Greater Bay Area[126] Operational Efficiency and Challenges - The net cash flow from operating activities decreased by 18.78% to ¥246,886,601.24 from ¥303,957,547.40 in 2020[6] - The company has effectively controlled costs and improved production efficiency, leading to reduced equipment expenditure[101] - The company is implementing measures to mitigate the impact of recurring COVID-19 outbreaks on plasma collection and production stability[131] - The company faces risks related to raw material supply shortages due to strict regulations on new plasma collection stations and the impact of COVID-19[130] Corporate Governance and Management - The company maintains complete independence from its controlling shareholders in personnel, financial, asset, institutional, and business aspects[138] - The company has established an independent financial department with a strict financial supervision system and does not share bank accounts with its controlling shareholders[139] - The company has a well-defined organizational structure with independent operational management, including procurement, production, and sales departments[139] - The company has established a performance-oriented evaluation and incentive mechanism for senior management, linking their compensation to the company's operational performance[187] Employee and Board Information - The total number of employees at the end of the reporting period was 759, with 406 in the parent company and 353 in major subsidiaries[173] - The company emphasizes employee training, implementing a three-tier training system to enhance employee capabilities and meet strategic development needs[179] - The company has a diverse board of directors and management team, with various members holding key positions since 2019 and 2021[145] - The company reported a leadership change with the resignation of several board members and executives, including Chairman Zhang Zhan and CFO Liu Xianzhong, due to work-related reasons[147][150] Compliance and Internal Control - The company has implemented a comprehensive internal control system to mitigate operational risks and ensure effective management[193] - There were no significant internal control deficiencies reported during the year 2021[195] - The internal control audit report was disclosed on April 15, 2022, confirming the absence of major defects[198] - The company has complied with the requirements set by the Shenzhen Securities Regulatory Bureau for improving governance and operational standards[200]

Financial Performance - The company's revenue for Q3 2021 reached ¥280,968,618.02, representing a 40.41% increase year-over-year[4] - Net profit attributable to shareholders was ¥67,712,645.79, up 55.76% compared to the same period last year[4] - The net profit excluding non-recurring gains and losses was ¥65,593,312.17, reflecting a 57.66% increase year-over-year[4] - Total revenue for the third quarter of 2021 was CNY 616,756,759.63, compared to CNY 607,659,905.15 in the same period of 2020, representing a year-over-year increase of approximately 1.8%[27] - Net profit for Q3 2021 reached 137,229,657.84 CNY, up from 120,328,073.29 CNY in Q3 2020, indicating an increase of about 14.1%[32] - Operating profit for Q3 2021 was 157,918,655.46 CNY, compared to 143,844,697.29 CNY in Q3 2020, marking an increase of about 9.3%[30] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,904,958,819.16, a 3.75% increase from the end of the previous year[7] - Total assets amounted to CNY 1,904,958,819.16 as of September 30, 2021, compared to CNY 1,836,144,030.49 at the end of 2020, showing an increase of approximately 3.7%[25] - Total liabilities decreased to CNY 184,446,406.65 from CNY 212,361,275.82, indicating a reduction of about 13.1% year-over-year[25] - The company’s investment in Guangzhou Hanteng Biotechnology Co., Ltd. led to a 234.72% increase in other non-current financial assets[9] Shareholder Equity - Shareholders' equity attributable to the company reached ¥1,700,961,514.72, marking a 6.06% increase from the previous year[7] - The company's equity attributable to shareholders increased to CNY 1,700,961,514.72 from CNY 1,603,788,839.86, reflecting a growth of approximately 6.1%[25] - The number of common shareholders at the end of the reporting period was not specified, but the top ten shareholders held a significant portion of shares, with the largest shareholder owning 65.25%[16] Cash Flow - Cash flow from operating activities showed a net decrease of 43.42% year-over-year, totaling ¥120,331,844.55[4] - Cash flow from operating activities for Q3 2021 was 120,331,844.55 CNY, a significant decrease from 212,679,086.22 CNY in Q3 2020, indicating a decline of about 43.3%[36] - The company reported a 40.59% decrease in cash and cash equivalents compared to the end of the previous year, primarily due to repayment of short-term loans[9] - Cash and cash equivalents decreased to CNY 280,102,189.58 as of September 30, 2021, down from CNY 471,468,969.66 at the end of 2020, indicating a decline of about 40.5%[19] - The net increase in cash and cash equivalents was -$191,366,780.08, compared to a positive increase of $161,809,959.17 previously[40] - The ending balance of cash and cash equivalents was $280,008,234.42, down from $466,416,331.35 at the end of the previous period[40] Expenses and Costs - Total operating costs for Q3 2021 were 463,900,624.08 CNY, slightly lower than 471,806,550.33 CNY in Q3 2020, showing a decrease of approximately 1.9%[30] - Research and development expenses increased to 34,650,925.82 CNY in Q3 2021, compared to 28,649,770.30 CNY in Q3 2020, reflecting a growth of approximately 21%[30] - The company's tax expenses for Q3 2021 were 20,385,987.71 CNY, down from 22,339,569.18 CNY in Q3 2020, reflecting a decrease of about 8.8%[30] Other Financial Metrics - The company’s basic earnings per share for Q3 2021 was ¥0.2986, a 10.59% increase year-over-year[4] - The company reported a basic earnings per share of 0.6070 CNY for Q3 2021, down from 0.7428 CNY in Q3 2020, representing a decrease of approximately 18.2%[33] - The company experienced a 320.25% increase in credit impairment losses compared to the same period last year, mainly due to increased provisions for bad debts[12] - Other income for Q3 2021 was reported at 7,555,275.50 CNY, compared to 6,797,290.61 CNY in Q3 2020, indicating an increase of approximately 11.2%[30] Investment Activities - Investment activities cash outflow totaled $213,160,067.70, compared to $119,360,636.14 in the previous period, indicating a significant increase[40] - Net cash flow from investment activities was -$213,125,767.70, worsening from -$118,903,374.34 year-over-year[40] Financing Activities - Cash inflow from financing activities was $75,000,000.00, down from $260,000,000.00 in the previous period[40] - Cash outflow from financing activities amounted to $173,572,856.93, compared to $191,965,752.71 previously, showing a decrease[40] - Net cash flow from financing activities was -$98,572,856.93, contrasting with a positive $68,034,247.29 in the prior period[40] Audit Status - The third quarter report was not audited, indicating potential limitations in the reliability of the financial data presented[41]

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 335,788,141.61, a decrease of 17.61% compared to CNY 407,556,862.46 in the same period last year[32]. - The net profit attributable to shareholders of the listed company was CNY 69,960,029.07, down 9.73% from CNY 77,500,387.25 in the previous year[32]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 65,914,936.94, a decrease of 11.57% compared to CNY 74,538,412.22 last year[32]. - The net cash flow from operating activities was CNY 44,354,483.29, a significant decline of 77.17% from CNY 194,322,683.37 in the same period last year[32]. - Basic earnings per share were CNY 0.3085, down 35.16% from CNY 0.4758 in the previous year[32]. - Total assets at the end of the reporting period were CNY 1,796,231,288.84, a decrease of 2.17% from CNY 1,836,144,030.49 at the end of the previous year[32]. - The net assets attributable to shareholders of the listed company increased by 1.84% to CNY 1,633,248,868.93 from CNY 1,603,788,839.86 at the end of the previous year[32]. - The company's gross profit margin improved as operating costs decreased by 23.25% to ¥199,846,790.10 from ¥260,391,640.47[84]. - The company reported a net cash flow from operating activities of ¥44,354,483.29, a significant decrease of 77.17% compared to ¥194,322,683.37 in the previous year[84]. - The company’s financial expenses increased by 157.53% to -¥4,432,718.02, primarily due to increased deposit interest[84]. Operational Highlights - In the first half of 2021, the company achieved operating revenue of 336 million yuan and a net profit attributable to shareholders of 70 million yuan[42]. - The company added 12,295 new plasma donors during the reporting period, a year-on-year increase of 3,434 donors, and completed plasma collection of 215 tons[43]. - The company maintained a 100% pass rate for GMP inspections, indicating strong product quality control[44]. - The company achieved a 100% batch release qualification rate for its products, ensuring safety and effectiveness throughout the production process[60]. - The company completed its plasma collection target for the first half of the year, maintaining a leading position in the industry with stable growth in its Waning plasma station[60]. - The company has established 8 single plasma collection stations, with the number of plasma donors and collection volume reaching new highs during the reporting period[73]. - The company holds 21 approved specifications across three major categories of blood products, with a high plasma utilization rate due to advanced production methods[74]. Market and Industry Insights - The actual plasma demand in China is estimated to exceed 14,000 tons, while the total plasma collection in 2020 was over 8,300 tons, indicating a significant supply-demand gap[65]. - The blood products industry is characterized by high barriers to entry and strict regulations, with a decreasing number of approved production enterprises[66]. - The global blood products market is highly concentrated, with the top five companies holding approximately 85% of the market share[63]. - The domestic blood products market is expected to grow due to increasing clinical demand and an aging population, despite a current supply shortage[66]. Research and Development - The human coagulation factor VIII is nearing completion of phase III clinical trials, with plans to submit a new drug application within the year[46]. - Research and development investment increased by 10.37% to ¥20,078,809.70, compared to ¥18,191,716.09 in the previous year[84]. - The company is committed to improving its R&D project management to align with market trends and reduce the risk of product development delays[110]. Sales and Marketing Strategies - The company is focusing on enhancing its sales channels and academic promotion efforts to drive product sales to new heights[58]. - The company is adopting aggressive sales policies and increasing academic investments to expand market reach amid intensified competition in blood products[110]. - The company successfully opened the market for its products in tier-three hospitals domestically, while also exporting key products to Venezuela and Brazil, marking a successful entry into international markets[60]. Environmental and Social Responsibility - The company reported a total wastewater discharge of 22,208 tons, with a permitted discharge limit of 173.2 tons per day, indicating compliance with environmental standards[125]. - The company operates two emission outlets for boiler exhaust, with nitrogen oxides measured at 35 mg/m³, adhering to the national emission standards[125]. - The company has committed to social responsibility initiatives, raising 32,705 yuan for various charitable activities during the reporting period[144]. - The company has established comprehensive environmental management systems, including wastewater treatment, to ensure compliance with environmental laws and regulations[145]. - The company emphasizes employee welfare, providing regular health checks and a supportive work environment[140]. Governance and Shareholder Relations - The company has established a robust governance structure to protect shareholder rights and ensure transparent information disclosure[139]. - The total number of ordinary shareholders at the end of the reporting period was 10,963, with significant shareholders including the State-owned Assets Supervision and Administration Commission holding 65.25%[191]. - The top ten unrestricted ordinary shareholders held a total of 172,000,000 shares, with the largest shareholder owning 147,987,000 shares[192]. - The company has not distributed cash dividends or bonus shares for the half-year period[115]. - The first phase of the employee stock ownership plan was completed with the purchase of 390,900 shares at an average price of RMB 51.515 per share, totaling RMB 20.14 million[119]. Compliance and Risk Management - The company plans to enhance its quality management system in response to compliance risks in the blood products industry, which is highly regulated by the government[106]. - The company has implemented a three-tier safety management system to mitigate risks associated with production safety accidents[107]. - The company is facing potential risks due to the COVID-19 pandemic affecting plasma collection, which may lead to temporary suspension of operations[108]. - There were no significant lawsuits or arbitration matters during the reporting period[156]. - The company did not experience any non-operating fund occupation by controlling shareholders or related parties during the reporting period[152].

深圳市卫光生物制品股份有限公司 2021 年第一季度报告全文 深圳市卫光生物制品股份有限公司 2021 年第一季度报告 2021 年 04 月 1 深圳市卫光生物制品股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人张战、主管会计工作负责人刘现忠及会计机构负责人(会计主管 人员)黄悝声明：保证季度报告中财务报表的真实、准确、完整。 2 深圳市卫光生物制品股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ ...